Share-based Payment Arrangement, Expense of Stoke Therapeutics, Inc. from 30 Jun 2018 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Stoke Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2018 to 30 Sep 2025.
  • Stoke Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $8,039,000, a 7.3% increase year-over-year.
  • Stoke Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $29,529,000, a 12% increase year-over-year.
  • Stoke Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $27,470,000, a 8.8% increase from 2023.
  • Stoke Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $25,257,000, a 11% increase from 2022.
  • Stoke Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $22,854,000, a 39% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Stoke Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $29,529,000 $8,039,000 +$545,000 +7.3% 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $28,984,000 $7,598,000 +$171,000 +2.3% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $28,813,000 $6,753,000 +$1,343,000 +25% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $27,470,000 $7,139,000 +$1,081,000 +18% 01 Oct 2024 31 Dec 2024 10-K 18 Mar 2025 2024 FY
Q3 2024 $26,389,000 $7,494,000 +$942,000 +14% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025 2025 Q3
Q2 2024 $25,447,000 $7,427,000 +$667,000 +9.9% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $24,780,000 $5,410,000 -$477,000 -8.1% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $25,257,000 $6,058,000 +$268,000 +4.6% 01 Oct 2023 31 Dec 2023 10-K 18 Mar 2025 2024 FY
Q3 2023 $24,989,000 $6,552,000 +$626,000 +11% 01 Jul 2023 30 Sep 2023 10-Q 05 Nov 2024 2024 Q3
Q2 2023 $24,363,000 $6,760,000 +$597,000 +9.7% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024 2024 Q2
Q1 2023 $23,766,000 $5,887,000 +$912,000 +18% 01 Jan 2023 31 Mar 2023 10-Q 06 May 2024 2024 Q1
Q4 2022 $22,854,000 $5,790,000 +$1,104,000 +24% 01 Oct 2022 31 Dec 2022 10-K 25 Mar 2024 2023 FY
Q3 2022 $21,750,000 $5,926,000 +$1,312,000 +28% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $20,438,000 $6,163,000 +$1,711,000 +38% 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023 2023 Q2
Q1 2022 $18,727,000 $4,975,000 +$2,277,000 +84% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $16,450,000 $4,686,000 +$3,106,000 +197% 01 Oct 2021 31 Dec 2021 10-K 06 Mar 2023 2022 FY
Q3 2021 $13,344,000 $4,614,000 +$2,829,000 +158% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $10,515,000 $4,452,000 +$2,803,000 +170% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2022 Q2
Q1 2021 $7,712,000 $2,698,000 +$1,944,000 +258% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q4 2020 $5,768,000 $1,580,000 +$868,000 +122% 01 Oct 2020 31 Dec 2020 10-K 10 Mar 2022 2021 FY
Q3 2020 $4,900,000 $1,785,000 +$1,054,000 +144% 01 Jul 2020 30 Sep 2020 10-Q 08 Nov 2021 2021 Q3
Q2 2020 $3,846,000 $1,649,000 +$1,351,000 +453% 01 Apr 2020 30 Jun 2020 10-Q 10 Aug 2021 2021 Q2
Q1 2020 $2,495,000 $754,000 +$573,000 +317% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q4 2019 $1,922,000 $712,000 01 Oct 2019 31 Dec 2019 10-K 09 Mar 2021 2020 FY
Q3 2019 $731,000 +$691,000 +1728% 01 Jul 2019 30 Sep 2019 10-Q 12 Nov 2020 2020 Q3
Q2 2019 $298,000 +$221,000 +287% 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020 2020 Q2
Q1 2019 $181,000 01 Jan 2019 31 Mar 2019 10-Q 15 May 2020 2020 Q1
Q3 2018 $40,000 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q2 2018 $77,000 01 Apr 2018 30 Jun 2018 10-Q 14 Aug 2019 2019 Q2

Stoke Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $27,470,000 +$2,213,000 +8.8% 01 Jan 2024 31 Dec 2024 10-K 18 Mar 2025 2024 FY
2023 $25,257,000 +$2,403,000 +11% 01 Jan 2023 31 Dec 2023 10-K 18 Mar 2025 2024 FY
2022 $22,854,000 +$6,404,000 +39% 01 Jan 2022 31 Dec 2022 10-K 25 Mar 2024 2023 FY
2021 $16,450,000 +$10,682,000 +185% 01 Jan 2021 31 Dec 2021 10-K 06 Mar 2023 2022 FY
2020 $5,768,000 +$3,846,000 +200% 01 Jan 2020 31 Dec 2020 10-K 10 Mar 2022 2021 FY
2019 $1,922,000 +$1,682,000 +701% 01 Jan 2019 31 Dec 2019 10-K 09 Mar 2021 2020 FY
2018 $240,000 01 Jan 2018 31 Dec 2018 10-K 23 Mar 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.